Pune: Fast Laboratory Artificial Antibody Cocktails – One of the most expensive drugs ever used against Covid-19 – has changed from the drug “used economily” into one “widely used”, almost replaces some of the usual drugs.
Treating doctors from all over the country has started using it as the first treatment line, especially for class patients who gave fitting on therapeutic criteria.
But experts from the National Covid Task Force have warned of their non-feather use.
This drug is not a “magic bullet” and can only be used in patients who are carefully chosen with risk factors, stress experts.
Head of Ruby Hall Clinic based in Pune Zirce said, “Cocktail antibodies are widely used as the first care lines for covid patients who are light and asymptomatic with comorbidity to prevent hospitalization and death.
This does not only occur in India but throughout the world.” Chennai Global Gleneagles Global Hospital Infectious Diseases Subramanian Subramanian Experts Swaminathan said, “None of our patients we use cocktail antibody therapy are needed inpatient.
Promising results have significantly increases its use.” Doctor Aniket Joshi, member of the Association of Indian Doctors ( API), said, “Patients with comorbidity are more likely to be serious.
This therapy is found very useful in it.
This raises the cost of treatment.
Even doctors in small cities use it.” Cocktail antibodies have become the first treatment line for many patients who are sick with existing medical conditions um, said Deenanath Mangeshkar Hospital Infectious Diseases Parikshit Prayag.
Choosing the right patient is the key.
“Those who have many risk factors for the development of the disease, are in their courses and do not have antibodies, to begin, are the most profitable patients,” said Prayag, an American Council certified expert in internal treatment and infectious diseases.
Cocktail antibody therapy – Casarivimab and IMdevimab – almost replacing drugs such as favipirailavir and inhalation budesonide.
“Cocktail antibody drugs have given us a good choice in certain patients.
It seems more promising compared to drugs such as Favipiravir.
However, the cost remains a barrier factor,” Prayag said.
Doctor of the Nanavati Hospital based in Mumbai Salil Bendre said, “I am the first to use therapy in our hospital.
Positive care results after therapy has fostered the trust of doctors about the safety and efficacy during that period.” Covid patients are light and young without Comorbidity and those who find unreachable therapy are still treated with covid drugs commonly used as Favipirailavir and others.
“Therapy costs RS63,000 per patient and therefore, still beyond the reach of many,” said Ameet Dravid’s infectious disease, who used it in 67 patients in the past two months.
Everything is improving and prohibiting one, no hospitalization is needed.
Experts from SATGK National Covid assignments warn to oppose using drugs not severely.
“This drug is not a magical bullet.
The use needs individual,” said Sanjay Pujari, a member of the National Covid Task Force.